Daraxonrasib Shows Survival Benefit in Pancreatic Cancer Phase 3 Trial

Context Pancreatic cancer remains one of the deadliest malignancies, with limited treatment options and low survival rates. For decades, the KRAS gene—responsible for regulating cell growth—was deemed impossible to drug when mutated, leaving chemotherapy as the mainstay. Recent scientific progress has produced molecules that can bind mutant KRAS and block its signaling.

Key Facts In the randomized controlled trial, patients receiving daraxonrasib plus chemotherapy lived a median of 13.2 months, compared with 6.7 months for those receiving chemotherapy alone. The study enrolled several hundred participants, though the exact sample size was not disclosed in the released data. Nearly 90% of pancreatic tumors harbor a KRAS mutation, which the drug is designed to target. Oncologist Chris Chen of Stanford called the outcome an "earth‑shattering moment" in pancreatic cancer.

What It Means The trial demonstrates a causal improvement in survival attributable to adding daraxonrasib to chemotherapy, thanks to its randomized design. For patients, the regimen offers a potentially longer life without requiring intravenous infusions, as the drug is taken orally. While chemotherapy remains the standard of care, the KRAS inhibitor could become a complementary option, especially for those who have already received prior chemo. Regulators have flagged daraxonrasib for high‑priority review, which may accelerate approval.

What to Watch Next Researchers await formal regulatory submission and anticipate data on quality of life and side‑effect profiles. Ongoing studies will also explore combining daraxonrasib with emerging approaches such as mRNA vaccines to further extend benefit.